Last updated: August 1, 2026
Oxyphenbutazone has no identifiable active clinical-development program, meaningful current commercial market, or viable modern regulatory pathway. The drug is an older pyrazolidinedione nonsteroidal anti-inflammatory drug related to phenylbutazone. Its historical use ended after serious blood-related toxicity, including agranulocytosis and aplastic anemia. Current commercial potential is effectively negligible because safer NSAIDs, regulatory restrictions, expired intellectual property, and limited clinical demand remove the main drivers of pharmaceutical investment.
What is the current clinical-trial status of oxyphenbutazone?
No active interventional clinical-trial program for oxyphenbutazone is identified in major public trial registries. The drug has no established role in current development for arthritis, pain, inflammation, oncology, or another therapeutic indication.
| Clinical-development metric |
Current assessment |
| Active pivotal trials |
None identified |
| Active Phase 1 trials |
None identified |
| Active Phase 2 or Phase 3 trials |
None identified |
| Modern regulatory development program |
None identified |
| Current clinical-trial sponsor |
None identified |
| Current investigational indication |
None identified |
| Biosimilar development |
Not applicable |
| Generic development opportunity |
Commercially immaterial |
Oxyphenbutazone was developed as an anti-inflammatory and analgesic agent. It is pharmacologically related to phenylbutazone and has historically been used in inflammatory rheumatic disorders. Its clinical use declined because of severe and sometimes fatal hematologic adverse events, particularly bone-marrow suppression and agranulocytosis.
ClinicalTrials.gov and other contemporary trial registries are designed primarily to capture modern prospective studies. Historical studies involving oxyphenbutazone may not appear in current registry records, especially studies conducted before registration requirements became standard. The absence of an active registry program is nevertheless consistent with the drug's discontinued commercial and regulatory status (National Library of Medicine, n.d.).
What is oxyphenbutazone and how was it used?
Oxyphenbutazone is a pyrazolidinedione NSAID and a hydroxylated derivative associated with phenylbutazone metabolism. It was marketed historically under the brand name Tanderil in some jurisdictions.
The drug was used for inflammatory conditions including:
- Rheumatoid arthritis
- Osteoarthritis
- Ankylosing spondylitis
- Acute musculoskeletal inflammation
- Other painful inflammatory disorders
Its mechanism involved inhibition of prostaglandin synthesis through cyclooxygenase pathway activity. The clinical value of that mechanism was later outweighed by its systemic safety liabilities.
Oxyphenbutazone's most material safety concerns included:
- Agranulocytosis
- Aplastic anemia
- Leukopenia
- Thrombocytopenia
- Gastrointestinal bleeding
- Renal toxicity
- Hepatic adverse effects
- Severe hypersensitivity reactions
The hematologic risks were particularly important because they were not adequately offset by a differentiated efficacy profile. Modern NSAIDs and targeted anti-inflammatory therapies provide more favorable risk-benefit options for most of the same indications.
What is the FDA regulatory status of oxyphenbutazone?
Oxyphenbutazone does not have an active U.S. commercial position comparable with currently marketed prescription NSAIDs. It is not a current standard-of-care product in the United States, and no active FDA development program is publicly established.
| FDA and U.S. regulatory question |
Status |
| Current FDA-approved commercial product |
No current marketed product identified |
| Current U.S. prescription market |
No meaningful active market identified |
| Current FDA clinical program |
None identified |
| Current pediatric exclusivity |
None |
| Current orphan-drug exclusivity |
None |
| Current new chemical entity exclusivity |
None |
| Current qualified infectious-disease exclusivity |
None |
| Current 180-day generic exclusivity event |
None identified |
The product's historical approval and marketing status varied by country. Withdrawal, discontinuation, or nonrenewal decisions were influenced by blood dyscrasia risk and the availability of alternatives. A historical authorization in one jurisdiction should not be interpreted as evidence of current regulatory availability elsewhere.
What is the Orange Book status of oxyphenbutazone?
Oxyphenbutazone has no meaningful current Orange Book patent or exclusivity position. A current branded product is not identified as an active U.S. reference product with commercial patent protection.
The Orange Book records FDA-approved drug products and related patent and exclusivity information. An old active ingredient may have historical regulatory records without supporting a current commercial product, patent listing, or generic-launch opportunity (U.S. Food and Drug Administration, n.d.-a).
| Orange Book issue |
Commercial implication |
| Active reference-listed drug |
Not identified |
| Listed formulation patent |
None of current commercial relevance identified |
| Listed method-of-use patent |
None of current commercial relevance identified |
| Active regulatory exclusivity |
None |
| Paragraph IV dispute |
None identified |
| Current ANDA competition |
No commercially meaningful activity identified |
When did oxyphenbutazone lose exclusivity?
Any composition-of-matter, formulation, or use patents associated with the original development period would have expired decades ago. Oxyphenbutazone therefore has no remaining patent-based exclusivity.
The precise expiration date of a historical patent family is not a useful commercial indicator because:
- The original product has long passed the ordinary patent term.
- Any relevant original patents would predate modern U.S. patent-term restoration rules.
- No current formulation or delivery-system patent has been identified as creating a market barrier.
- The principal barrier is regulatory and clinical risk, not intellectual property.
What patents protect oxyphenbutazone?
No active, commercially significant patent estate protecting oxyphenbutazone as an active pharmaceutical ingredient, formulation, method of use, or manufacturing process has been identified.
| Patent category |
Current assessment |
| Composition of matter |
Expired |
| Salt or polymorph |
No active commercially relevant protection identified |
| Oral formulation |
No active commercially relevant protection identified |
| Injectable formulation |
No active commercially relevant protection identified |
| Transdermal or modified-release delivery |
No active commercially relevant protection identified |
| Method of treatment |
Historical protection, if any, expired |
| Manufacturing process |
No active barrier identified |
Patent barriers are therefore not the reason oxyphenbutazone is absent from the market. A company could face more substantial obstacles from regulatory acceptability, clinical safety, product liability, manufacturing controls, and commercial substitution.
Are there Paragraph IV challenges or patent litigation involving oxyphenbutazone?
No current Paragraph IV challenge, ANDA patent litigation, or active Hatch-Waxman dispute involving oxyphenbutazone is identified.
The absence of litigation reflects the lack of a commercially protected reference product rather than a strong patent position. Paragraph IV litigation generally requires an active listed drug, relevant Orange Book patents, and a generic applicant with a credible commercial launch plan. Those conditions are not present for oxyphenbutazone.
| Litigation category |
Current status |
| Hatch-Waxman patent case |
None identified |
| Paragraph IV notice |
None identified |
| Preliminary injunction |
None identified |
| Settlement agreement |
None identified |
| License settlement |
None identified |
| Antitrust dispute |
None identified |
| Product-liability exposure |
Historical risk category, not an active patent dispute |
What is the market size for oxyphenbutazone?
Oxyphenbutazone has no measurable global branded pharmaceutical market of commercial significance. Public market-research firms do not generally report a standalone revenue category for the drug because it is not an active growth product and has no substantial current sales base.
| Market metric |
Projection |
| Current global branded sales |
Effectively zero or immaterial |
| Current U.S. sales |
No meaningful commercial sales identified |
| Hospital-use market |
No meaningful current market identified |
| Active generic market |
No meaningful market identified |
| Five-year revenue growth |
Not a meaningful positive-growth category |
| Commercial market-entry probability |
Very low |
| Investment case |
Unattractive without a noncommercial research rationale |
A conventional market forecast would produce misleading precision. Oxyphenbutazone does not have the usual inputs for a pharmaceutical forecast: no active brand, no expanding indication, no current trial pipeline, no identifiable prescriber base, and no meaningful reimbursement opportunity.
What is the revenue exposure for historical manufacturers?
Historical manufacturers and licensees may have generated revenue during the period when oxyphenbutazone was marketed for rheumatic disease. Current revenue exposure is not material because:
- The historical brand has been discontinued or is not commercially active in major markets.
- Competing NSAIDs have replaced the product.
- Safety concerns limit physician adoption.
- No current premium formulation or specialty indication supports pricing power.
- No active intellectual-property strategy supports a relaunch.
Any residual sales in small or poorly documented markets would not change the global commercial assessment.
How strong is the patent estate for oxyphenbutazone?
The patent estate is commercially weak because it is expired and does not create a defensible market position. Patent strength should be separated from the technical ability to manufacture the molecule.
Intellectual-property assessment
| Factor |
Assessment |
| Patent life |
Exhausted |
| Patent breadth |
No current relevant protection |
| Formulation differentiation |
Limited |
| Use-claim differentiation |
Limited and historically focused |
| Freedom to operate |
Likely broad from an expired-patent perspective |
| Regulatory exclusivity |
None |
| Litigation leverage |
None |
| Commercial defensibility |
Very low |
A company could manufacture oxyphenbutazone without confronting a modern blocking patent estate, but that does not make the product commercially attractive. The absence of patent barriers increases theoretical access while the lack of demand and unfavorable safety profile suppresses the business case.
What formulation patents and delivery systems protect oxyphenbutazone?
No current formulation patent strategy is evident for oxyphenbutazone. Historical use was primarily associated with conventional oral dosage forms. There is no established commercial extended-release, transdermal, depot, inhaled, or targeted-delivery platform for the drug.
A reformulation strategy would face several problems:
- Systemic hematologic toxicity may not be eliminated by changing release kinetics.
- A new delivery system could require substantial pharmacokinetic and safety work.
- The drug lacks a clear clinical advantage over modern NSAIDs.
- A reformulation would have to establish a new risk-benefit profile.
- Any new patent would protect the delivery system, not restore broad active-ingredient exclusivity.
A reformulation could theoretically create intellectual property, but it would not automatically create regulatory acceptability or market demand.
Is there a biosimilar risk for oxyphenbutazone?
Biosimilar risk is not applicable. Oxyphenbutazone is a small-molecule chemical drug, not a biologic. Any competing product would be evaluated as a generic or reformulated small molecule under the applicable national pathway.
The practical competitive risk comes from substitution by established NSAIDs and other anti-inflammatory therapies, including:
- Ibuprofen
- Naproxen
- Diclofenac
- Celecoxib
- Meloxicam
- Etoricoxib in markets where approved
- Corticosteroids for selected inflammatory conditions
- Disease-modifying antirheumatic drugs for rheumatoid arthritis
- Biologic therapies for severe autoimmune disease
These alternatives have stronger current clinical positioning, broader evidence bases, and established manufacturing and distribution networks.
How does oxyphenbutazone compare with modern NSAIDs?
| Attribute |
Oxyphenbutazone |
Modern NSAIDs |
| Current availability |
Minimal or absent |
Broad |
| Hematologic safety |
Major historical concern |
Generally more manageable, though not risk-free |
| Gastrointestinal risk |
Significant |
Varies by agent and dose |
| Cardiovascular evidence |
Limited by modern standards |
Extensive for major products |
| Clinical guidelines |
Largely absent |
Widely incorporated |
| Generic competition |
Not commercially significant |
Extensive |
| Prescriber familiarity |
Historical |
High |
| Patent opportunity |
Expired |
Depends on product and formulation |
| Commercial outlook |
Negligible |
Established or indication-specific |
Oxyphenbutazone is disadvantaged in both safety and commercial positioning. It does not provide a clear efficacy advantage that would justify a higher-risk profile.
What manufacturing and IP barriers affect oxyphenbutazone?
The active pharmaceutical ingredient is an old small molecule, so basic chemical manufacturing is unlikely to present a novel intellectual-property barrier. The more material issues are quality, regulatory compliance, toxicology, and supply-chain economics.
Potential manufacturing concerns include:
- Control of impurities and degradation products
- Demonstration of batch consistency
- Validated analytical methods
- Good Manufacturing Practice compliance
- Stability and shelf-life data
- Control of residual solvents
- Pharmacopoeial specifications
- Supply of qualified starting materials
- Pharmacovigilance and adverse-event monitoring
For an obsolete or highly restricted drug, production at commercial scale may also be economically inefficient. Minimum-order quantities, limited active-ingredient demand, and specialized regulatory controls can make supply more expensive than the nominally low cost of the molecule suggests.
Are there licensing deals for oxyphenbutazone?
No current material licensing transaction involving oxyphenbutazone has been identified. Historical arrangements may have involved brand distribution, regional commercialization, or manufacturing rights, but they do not represent an active partnering market.
A modern licensing transaction would require a differentiated asset, such as:
- A new low-exposure formulation
- A validated niche indication
- A delivery system that changes the safety profile
- A veterinary or laboratory application
- A use in a jurisdiction with a specific unmet need
No such active program is publicly established.
What are the likely generic launch scenarios?
A conventional generic launch is unlikely to produce a viable commercial return.
| Launch scenario |
Probability |
Commercial assessment |
| Standard oral generic in the U.S. |
Very low |
No meaningful reference-product demand |
| Generic launch in a small international market |
Low |
Potentially limited, fragmented demand |
| Hospital or compassionate-use supply |
Low |
Narrow and irregular demand |
| Reformulated product |
Very low |
Requires new clinical and regulatory investment |
| Veterinary or research supply |
Low to moderate in niche channels |
Not a conventional pharmaceutical opportunity |
| Broad global relaunch |
Extremely low |
Unfavorable safety and substitution profile |
A company seeking to reintroduce oxyphenbutazone would likely need to address the drug's historical hematologic risks through contemporary toxicology, clinical pharmacology, risk-management planning, and jurisdiction-specific regulatory review. The expected return would not justify that investment under ordinary commercial assumptions.
What is the five-year market projection for oxyphenbutazone?
The five-year projection is flat at an immaterial level. No evidence supports a return to broad human pharmaceutical use.
Base case
The drug remains commercially inactive, with no significant clinical-trial activity, no meaningful patent litigation, and no material branded or generic revenue.
Upside case
A niche manufacturer supplies limited quantities for research, special-access, or local-market use. Revenue remains small and does not support a conventional global market category.
Downside case
Existing residual supply disappears as manufacturers discontinue production and regulators maintain restrictions or nonapproval.
| Forecast period |
Expected market direction |
| 2025-2026 |
No meaningful clinical or commercial expansion |
| 2027-2028 |
Continued decline or stable immaterial niche supply |
| 2029-2030 |
No credible path to mainstream pharmaceutical relaunch |
Key Takeaways
- Oxyphenbutazone has no identifiable active clinical-trial program.
- The drug has no meaningful current FDA or Orange Book commercial position.
- Historical patents and any related exclusivity have expired.
- No current Paragraph IV challenge, patent litigation, or settlement agreement is identified.
- Biosimilar analysis does not apply because oxyphenbutazone is a small-molecule drug.
- Historical hematologic toxicity is the principal clinical barrier.
- Modern NSAIDs and disease-specific therapies have displaced oxyphenbutazone.
- Current global revenue is effectively zero or immaterial.
- A conventional generic launch is unlikely to achieve attractive commercial returns.
- The five-year outlook is flat at a negligible market level.
FAQs About Oxyphenbutazone Clinical Development and Market Potential
Is oxyphenbutazone still prescribed for arthritis?
It is not a standard contemporary treatment for arthritis in major pharmaceutical markets. Safer and better-established NSAIDs and disease-modifying therapies have replaced it.
Was oxyphenbutazone withdrawn because of aplastic anemia?
Serious blood disorders, including aplastic anemia and agranulocytosis, were among the major safety concerns associated with oxyphenbutazone and related pyrazolidinedione drugs.
Can a company still develop a generic oxyphenbutazone product?
The lack of active patent protection may permit development in principle, but regulatory, safety, demand, and commercial barriers make a conventional generic program unattractive.
Does oxyphenbutazone have orphan-drug potential?
No established orphan indication or active orphan-development program is identified. Orphan designation would not by itself resolve the drug's historical systemic toxicity or limited therapeutic differentiation.
Is oxyphenbutazone used in veterinary medicine?
Veterinary use depends on jurisdiction and product-specific authorization. The presence of historical or niche veterinary availability would not establish a significant human pharmaceutical market.
References
-
National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-b). FDA drug safety communications. https://www.fda.gov/drugs/drug-safety-and-availability
-
World Health Organization. (n.d.). WHO Model Formulary and international drug safety information. https://www.who.int/
-
National Center for Biotechnology Information. (n.d.). PubChem compound summary: Oxyphenbutazone. PubChem. https://pubchem.ncbi.nlm.nih.gov/
